Chen X, et al. - Experts undertook an appraisal of the role of CXCR1 in the prognosis of patients with metastatic renal cell carcinoma (mRCC) receiving tyrosine kinase inhibitors (TKIs) therapy. It was inferred that high CXCR1 expression pointed towards reduced benefit from TKIs therapy in patients with mRCC. The observed mechanism could be due to the enriched pathways of hypoxia and angiogenesis in CXCR1 positive patients. It was deduced that CXCR1 possibly served as a potential therapeutic target for mRCC.